NASDAQ:EXEL - Exelixis Stock Price, Forecast & News

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Exelixis, Inc. (NASDAQ:EXEL) posted its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported $0.31 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.19 by $0.12. The biotechnology company had revenue of $271.70 million for the quarter, compared to the consensus estimate of $228.17 million. Exelixis had a net margin of 64.05% and a return on equity of 25.55%. Exelixis's revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.44 earnings per share. View Exelixis' Earnings History.

Exelixis is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Exelixis.

Exelixis will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

12 brokerages have issued 12 month target prices for Exelixis' shares. Their forecasts range from $19.00 to $35.00. On average, they expect Exelixis' share price to reach $26.70 in the next twelve months. This suggests a possible upside of 25.4% from the stock's current price. View Analyst Price Targets for Exelixis.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.

Media headlines about EXEL stock have trended very negative on Thursday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Exelixis earned a coverage optimism score of -3.4 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Exelixis.

Exelixis saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 18,100,000 shares, an increase of 17.0% from the December 31st total of 15,470,000 shares. Based on an average trading volume of 2,940,000 shares, the days-to-cover ratio is currently 6.2 days. Approximately 6.2% of the shares of the stock are short sold. View Exelixis' Current Options Chain.

Some companies that are related to Exelixis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Gilead Sciences (GILD), Incyte (INCY), Intel (INTC), BioMarin Pharmaceutical (BMRN), Corbus Pharmaceuticals (CRBP) and Puma Biotechnology (PBYI).

Exelixis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (5.91%), State Street Corp (3.64%), FMR LLC (3.21%), AJO LP (2.51%), AQR Capital Management LLC (2.50%) and Farallon Capital Management LLC (2.47%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

EXEL stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, FMR LLC, Goldman Sachs Group Inc., Pictet Asset Management Ltd., Great West Life Assurance Co. Can, Fiera Capital Corp, UBS Group AG and Prudential Financial Inc.. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

EXEL stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, AJO LP, Bank of Montreal Can, Renaissance Technologies LLC, State Street Corp, First Trust Advisors LP, Acadian Asset Management LLC and Man Group plc. View Insider Buying and Selling for Exelixis.

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EXEL stock can currently be purchased for approximately $21.30.

Exelixis has a market capitalization of $6.47 billion and generates $853.83 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.43 on an earnings per share basis. Exelixis employs 484 workers across the globe.View Additional Information About Exelixis.

The official website for Exelixis is http://www.exelixis.com/.

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]